-
Company Insights
Innovation and Patenting activity of SGS SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SGS SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Insights
Innovation and Patenting activity of SG Micro Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SG Micro Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of SG Holdings Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SG Holdings Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Refractory Multiple Myeloma Drug Details: SG-2501 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Relapsed Multiple Myeloma Drug Details: SG-2501 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Primary Systemic Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Primary Systemic Amyloidosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Primary Systemic AmyloidosisDrug Details: SG-2501 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: SG-2501 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Chronic Lymphocytic Leukemia (CLL) Drug Details: SG-2501 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Diffuse Large B-Cell Lymphoma Drug Details: SG-2501 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SG-2501 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details: SG-2501...